Mutant of L1 protein of human papillomavirus type 66
US11464846B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 4, 2019 |
| Grant date | Oct 11, 2022 |
| Priority date | — |
| Expiry date | Jun 4, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/19
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a mutated HPV66 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV66 and HPV56, or HPV66, HPV56 and HPV53), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.